NO20064929L - Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes - Google Patents

Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes

Info

Publication number
NO20064929L
NO20064929L NO20064929A NO20064929A NO20064929L NO 20064929 L NO20064929 L NO 20064929L NO 20064929 A NO20064929 A NO 20064929A NO 20064929 A NO20064929 A NO 20064929A NO 20064929 L NO20064929 L NO 20064929L
Authority
NO
Norway
Prior art keywords
diabetes
treatment
type
sulfonamide
pyridine derivatives
Prior art date
Application number
NO20064929A
Other languages
English (en)
Norwegian (no)
Inventor
Gregory Raymond Bebernitz
Ramesh Chandra Gupta
Vikrant Vijaykumar Jagtap
Appaji Baburao Mandhare
Davinder Tuli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20064929L publication Critical patent/NO20064929L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20064929A 2004-04-02 2006-10-27 Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes NO20064929L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55918404P 2004-04-02 2004-04-02
PCT/EP2005/003456 WO2005095418A1 (fr) 2004-04-02 2005-04-01 Derives de sulfonamide-thiazolpyridine en tant qu'activateurs de glucokinase utiles dans le traitement du diabete de type 2

Publications (1)

Publication Number Publication Date
NO20064929L true NO20064929L (no) 2006-12-20

Family

ID=34963913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064929A NO20064929L (no) 2004-04-02 2006-10-27 Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes

Country Status (19)

Country Link
US (1) US7750020B2 (fr)
EP (1) EP1735322B1 (fr)
JP (1) JP4700684B2 (fr)
KR (1) KR100830007B1 (fr)
CN (1) CN1960995B (fr)
AR (1) AR050913A1 (fr)
AT (1) ATE524479T1 (fr)
AU (1) AU2005229416B2 (fr)
BR (1) BRPI0509573A (fr)
CA (1) CA2560689C (fr)
EC (1) ECSP066894A (fr)
IL (1) IL178151A0 (fr)
MA (1) MA28528B1 (fr)
NO (1) NO20064929L (fr)
PE (1) PE20061353A1 (fr)
PT (1) PT1735322E (fr)
RU (1) RU2412192C2 (fr)
TN (1) TNSN06315A1 (fr)
WO (1) WO2005095418A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2005229415B2 (en) * 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
JP2009513720A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換シクロアルキルピロロン
EP1951707A1 (fr) * 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Pyrrolones substitues utilises en tant que modulateurs allosteriques de glucokinase
JP2009513704A (ja) * 2005-11-01 2009-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしての置換ジヒドロイソインドロン
WO2007053662A1 (fr) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones utilisées comme modulateurs allostériques de la glucokinase
WO2007110449A1 (fr) 2006-03-29 2007-10-04 Euro-Celtique S.A. Composés de benzènesulfonamide et utilisation de ceux-ci
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (fr) 2006-04-13 2007-10-25 Euro-Celtique S.A. Composés à base de benzènesulfonamide et leur utilisation
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
RU2009105818A (ru) 2006-07-24 2010-08-27 Ф.Хоффманн-Ля Рош Аг (Ch) Пиразолы в качестве активаторов глюкокиназы
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
TW200902489A (en) * 2007-03-07 2009-01-16 Kyorin Seiyaku Kk Glucokinase-activating substance
WO2008119734A2 (fr) * 2007-03-29 2008-10-09 Novartis Ag Procédé de préparation de composés organiques
WO2008124118A1 (fr) 2007-04-09 2008-10-16 Purdue Pharma L.P. Composés benzènesulfonylés et leur utilisation
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8501955B2 (en) * 2007-10-08 2013-08-06 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal application
CN101417987B (zh) * 2007-10-24 2011-07-13 山东轩竹医药科技有限公司 具有磺酰胺甲酰哌嗪结构的dpp-iv抑制剂
KR20100113518A (ko) 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
EP2275414B1 (fr) * 2008-04-28 2015-06-10 Kyorin Pharmaceutical Co., Ltd. Dérivé d'amide cyclopentylacrylique
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
CA2735184C (fr) * 2008-09-11 2013-05-28 Pfizer Inc. Derives d'amides d'heteroaryles et leur utilisation comme activateurs de la glucokinase
GEP20156239B (en) 2009-03-11 2015-01-26 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
EP2822935B1 (fr) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-terminale (jnk)
WO2013173382A1 (fr) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophène sulfonamides et autres composés qui interagissent avec une protéine régulatrice de la glucokinase
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
CA2927917C (fr) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
WO2015164604A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
CA2972239A1 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
EP3273966B1 (fr) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
WO2016201370A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
CA2996978A1 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dependantes

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
MXPA01009814A (es) * 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
BR0110573A (pt) 2000-05-03 2003-04-01 Hoffmann La Roche Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
DE60113247T2 (de) 2000-05-03 2006-06-22 F. Hoffmann-La Roche Ag Hydantoin-enthaltende glucokinase aktivatoren
US6489485B2 (en) 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
AU6591401A (en) 2000-05-08 2001-11-20 Hoffmann La Roche Para-amine substituted phenylamide glucokinase activators
DE60106599T2 (de) 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
MXPA03000365A (es) 2000-07-20 2003-05-27 Hoffmann La Roche Bencenacetamida substituida con alfa-acilo y alfa-heteroatomo como activadores de la glucocinasa.
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
AU2002221902B2 (en) 2000-12-06 2006-11-23 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
CN100506807C (zh) 2001-12-21 2009-07-01 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
WO2003080585A1 (fr) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
UA80427C2 (en) 2002-04-26 2007-09-25 Hoffmann La Roche Substituted phenylacetamides and their use as glucokinase activators
US20070231874A1 (en) 2002-05-16 2007-10-04 Kenji Kamata Crystal of glucokinase protein, and method for drug design using the crystal
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
MXPA05003391A (es) 2002-10-03 2005-06-22 Hoffmann La Roche Indol-3-carboxamidas como activadores de glucocinasa.
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
SI1585739T1 (sl) 2003-01-06 2011-07-29 Lilly Co Eli Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (fr) 2003-02-11 2004-08-26 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
KR20050101208A (ko) 2003-02-13 2005-10-20 반유 세이야꾸 가부시끼가이샤 신규한 2-피리딘 카복사미드 유도체
WO2004076420A1 (fr) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. Derives d'heteroarylcarbamoylbenzene
AU2005229415B2 (en) 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
KR20080105180A (ko) 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
EP1824835A1 (fr) 2004-12-03 2007-08-29 Novo Nordisk A/S Composes heteroaromatiques activants de glukokinase
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos

Also Published As

Publication number Publication date
EP1735322B1 (fr) 2011-09-14
WO2005095418A1 (fr) 2005-10-13
PT1735322E (pt) 2012-01-12
RU2006138433A (ru) 2008-05-10
ECSP066894A (es) 2006-11-24
BRPI0509573A (pt) 2007-09-25
EP1735322A1 (fr) 2006-12-27
ATE524479T1 (de) 2011-09-15
AR050913A1 (es) 2006-12-06
KR20060131955A (ko) 2006-12-20
AU2005229416B2 (en) 2009-03-26
CA2560689C (fr) 2011-03-01
US20080103167A1 (en) 2008-05-01
KR100830007B1 (ko) 2008-05-15
IL178151A0 (en) 2006-12-31
JP2007530632A (ja) 2007-11-01
JP4700684B2 (ja) 2011-06-15
TNSN06315A1 (en) 2007-12-03
US7750020B2 (en) 2010-07-06
RU2412192C2 (ru) 2011-02-20
PE20061353A1 (es) 2006-12-29
MA28528B1 (fr) 2007-04-03
CN1960995B (zh) 2010-12-08
CA2560689A1 (fr) 2005-10-13
CN1960995A (zh) 2007-05-09
AU2005229416A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
NO20064929L (no) Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes
WO2007041365A3 (fr) Composes organiques
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
ATE539748T1 (de) Glucokinaseaktivatoren
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
NO20052159L (no) Substituert (tiazol-2-yl)-amid eller sulfonamid som glykokinase-aktivatorer nyttige ved behandling av type 2 diabetes.
UA101166C2 (ru) Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
DE602004017703D1 (de) Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
ATE521608T1 (de) Glucokinaseaktivatoren
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
NO20072665L (no) Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
PL381801A1 (pl) Pochodne mocznika, kompozycje zawierające pochodne mocznika oraz zastosowanie pochodnych mocznika do wytwarzania leku do leczenia skurczowej niewydolności serca
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
PE20050194A1 (es) Derivados de piridina-2-carboxamida como activadores de glucoquinasa
ATE374766T1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
GB0226930D0 (en) Chemical compounds
DE602006006461D1 (de) Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application